Skip Navigation

European Heart Journal 1996 17(4):564-573;
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by van Hemel, N. M.
Right arrow Articles by Vermeulen, F. E. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by van Hemel, N. M.
Right arrow Articles by Vermeulen, F. E. E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 The European Society of Cardiology

Continuation of antiarrhythmic drugs, or arrhythmia surgery after multiple drug failures

A randomized trial in the treatment of postinfarction ventricular tachycardia

N. M. van Hemel, J. H. Kingma, J. J. A. M. Defauw*, E. Hoogteijling-van Dusseldorp, J. C. Kelder, W. P. Beukema and F. E. E. Vermeulen*

Departments of Cardiology, St Antonius Hospital Nieuwegein, The Netherlands
*Cardiothoracic Surgery, St Antonius Hospital Nieuwegein, The Netherlands

Received 29 August 1995; accepted 20 September 1995.

Correspondence: Norbert M. van Hemel, MD, Department of Cardiology, St Antonius Hospital, P.O. Box 2500, 3430 EM Nieuwegein, The Netherlands

Abstract

BACKGROUND: In patients with postinfarction sustained ventricular tachycardia showing one or more antiarrhythmic drug failures, the question is how long to proceed with new drug trials before deciding to perform map-guided arrhythmia surgery. Although the techniques of this surgery developed rapidly in the early I 980s, this therapy may be offset by damage to residual left ventricular function. However, surgery has been shown to be very effective in selected groups of patients.

METHODS: A randomized study was carried out in patients with postinfarction ventricular tachycardia and eligible for arrhythmia surgery based on residual left ventricular function. Therapy failure was defined by the occurrence of the following events: spontaneous recurrence of ventricular tachycardia or ventricular fibrillation, sudden cardiac death, inducibility of sustained ventricular tachycardia or ventricular fibrillation with programmed stimulation of the heart, symptomatic non-sustained ventricular tachycardia requiring therapy or side-effects of antiarrhythmic drugs requiring withdrawal. In the drug limb, failure of the first antiarrhythmic drug was accepted but failure of a second and different drug was regarded as true therapy failure.

RESULTS: After randomization, antiarrhythmic drug therapy was administered in 33 patients, and 30 patients underwent surgery. Neither group differed in baseline characteristics, and the mean number of drug failures before randomization was 2·7 The Kaplan-Meier therapeutic failure of antiarrhythmic drugs was 39±11%, 42±11% and 51±18% at 0·5-, I- and 4-year follow-up, respectively, whereas the therapeutic failure of cardiac surgery was 37±11%, 37±11% and 50±20% at 0·5, I and 4 years, respectively, showing no statistical difference. The 1- and 4-year Kaplan-Meier survival of the antiarrhythmic drug-treated group was 91±6% and 78±15%, respectively, and of the surgical group 92±6% and 59±20%, respectively, and did not differ between either group. However, the relative risk for total cardiac death was higher in the surgical limb than in the drug limb (relative risk 2·2, CI 0·68–7·48).

CONCLUSION: This study demonstrated no difference between the therapeutic result of continuation of two different antiarrhythmic drugs and that of arrhythmia surgery. Despite the small number of patients studied, it is recommended that drug therapy should continue as long as this regimen is tolerated by the patient. When true drug refractoriness or side-effects of drugs arise, arrhythmia surgery offers a valuable alternative. However, when additional reasons for cardiac surgery exist, arrhythmia surgery should be undertaken earlier and may become the first choice of treatment of postinfarction ventricular tachycardia.

Key Words: Postinfarction • ventricular tachycardia • map-guided arrhythmia surgery • antiarrhythmic drug therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
U. O. von Oppell, D. Milne, A. Okreglicki, and R. N. Scott Millar
Surgery for ventricular tachycardia of left ventricular origin: risk factors for success and long-term outcome
Eur. J. Cardiothorac. Surg., November 1, 2002; 22(5): 762 - 770.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
S.G. Priori, E. Aliot, C. Blomstrom-Lundqvist, L. Bossaert, G. Breithardt, P. Brugada, A.J. Camm, R. Cappato, S.M. Cobbe, C. Di Mario, et al.
Task Force on Sudden Cardiac Death of the European Society of Cardiology
Eur. Heart J., August 2, 2001; 22(16): 1374 - 1450.
[PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
P. F.A. Bakker, F. de Lange, R. N.W. Hauer, R. Derksen, and J. M.T. de Bakker
Sequential map-guided endocardial resection for ventricular tachycardia improves outcome
Eur. J. Cardiothorac. Surg., April 1, 2001; 19(4): 448 - 454.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
J P Bourke, R W F Campbell, J M McComb, S S Furniss, J C Doig, and C J Hilton
Surgery for postinfarction ventricular tachycardia in the pre-implantable cardioverter defibrillator era: early and long term outcomes in 100 consecutive patients
Heart, August 1, 1999; 82(2): 156 - 162.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.